Allergan survives Combigan patent challenge

29-09-2015

Allergan survives Combigan patent challenge

360b / Shutterstock.com

Pharmaceutical company Allergan has survived an attempt by hedge fund Ferrum Ferro Capital (FFC) to invalidate a patent covering its Combigan (brimonidine and timolol) drug after the Patent Trial and Appeal Board (PTAB) opted not to institute an inter partes review (IPR).


Ferrum Ferro Capital; Allergan; PTAB; IPR; USPTO; Combigan; glaucoma

LSIPR